Type your tag names separated by a space and hit enter

Magnesium in CKD: more than a calcification inhibitor?

Abstract

Magnesium fulfils important roles in multiple physiological processes. Accordingly, a tight regulation of magnesium homeostasis is essential. Dysregulated magnesium serum levels, in particular hypomagnesaemia, are common in patients with chronic kidney disease (CKD) and have been associated with poor clinical outcomes. In cell culture studies as well as in clinical situations magnesium levels were associated with vascular calcification, cardiovascular disease and altered bone-mineral metabolism. Magnesium has also been linked to diseases such as metabolic syndrome, diabetes, hypertension, fatigue and depression, all of which are common in CKD. The present review summarizes and discusses the latest clinical data on the impact of magnesium and possible effects of higher levels on the health status of patients with CKD, including an outlook on the use of magnesium-based phosphate-binding agents in this context.

Links

Authors+Show Affiliations

Floege J

Division of Nephrology and Clinical Immunology, RWTH University of Aachen, Pauwelsstr. 30, 52057, Aachen, Germany, juergen.floege@rwth-aachen.de.

Source

Journal of nephrology 28:3 2015 Jun pg 269-77

MeSH

Animals
Bone and Bones
Comorbidity
Depression
Diabetes Mellitus
Dietary Supplements
Fatigue
Health Status
Humans
Hypertension
Kidney
Magnesium
Renal Insufficiency, Chronic
Risk Factors
Vascular Calcification

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25227765

Citation

Floege, Jürgen. "Magnesium in CKD: More Than a Calcification Inhibitor?" Journal of Nephrology, vol. 28, no. 3, 2015, pp. 269-77. Unbound PRIME, www.unboundmedicine.com/medline/citation/25227765/full_citation. Accessed February 23, 2019.

Floege J. Magnesium in CKD: more than a calcification inhibitor? J Nephrol. 2015;28(3):269-77.  https://www.unboundmedicine.com/medline/citation/25227765/full_citation. Accessed February 23, 2019.

Floege, J. (2015). Magnesium in CKD: more than a calcification inhibitor? Journal of Nephrology, 28(3), pp. 269-77. doi:10.1007/s40620-014-0140-6

Floege J. Magnesium in CKD: More Than a Calcification Inhibitor [Internet]. J Nephrol. 2015 [cited 2019 Feb 23];28(3):269-77. Available from: https://www.unboundmedicine.com/medline/citation/25227765/full_citation doi: 10.1007/s40620-014-0140-6

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Magnesium in CKD: more than a calcification inhibitor? A1 - Floege,Jürgen, Y1 - 2014/09/17/ PY - 2014/07/22/received PY - 2014/09/02/accepted PY - 2014/9/18/entrez PY - 2014/9/18/pubmed PY - 2016/2/18/medline SP - 269 EP - 77 JF - Journal of nephrology JO - J. Nephrol. VL - 28 IS - 3 N2 - Magnesium fulfils important roles in multiple physiological processes. Accordingly, a tight regulation of magnesium homeostasis is essential. Dysregulated magnesium serum levels, in particular hypomagnesaemia, are common in patients with chronic kidney disease (CKD) and have been associated with poor clinical outcomes. In cell culture studies as well as in clinical situations magnesium levels were associated with vascular calcification, cardiovascular disease and altered bone-mineral metabolism. Magnesium has also been linked to diseases such as metabolic syndrome, diabetes, hypertension, fatigue and depression, all of which are common in CKD. The present review summarizes and discusses the latest clinical data on the impact of magnesium and possible effects of higher levels on the health status of patients with CKD, including an outlook on the use of magnesium-based phosphate-binding agents in this context. SN - 1724-6059 UR - https://www.unboundmedicine.com/medline/citation/25227765/full_citation L2 - https://dx.doi.org/10.1007/s40620-014-0140-6 DB - PRIME DP - Unbound Medicine ER -